Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes

During the last decade, substantial advances have been made in the understanding of the complex molecular, immunological and cellular disturbances involved in the initiation as well as evolution of myelodysplastic syndromes (MDS). In 85% of the mainly frail and older patient population, anemia is pr...

Full description

Bibliographic Details
Main Authors: Anne Sophie Kubasch, Uwe Platzbecker
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:International Journal of Molecular Sciences
Subjects:
MDS
ESA
EMA
Online Access:https://www.mdpi.com/1422-0067/20/16/3853